19:51 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample, cell culture and mouse studies suggest inhibiting PAK1 or PAK4 could help treat drug-resistant BRAF-mutant melanoma. In tumor samples from metastatic melanoma patients, high primary tumor levels of PAK1 were associated with...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Yes-associated protein 1 (YAP1; YAP); p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1)

Hepatic disease INDICATION: Liver fibrosis Cell culture and mouse studies suggest inhibiting YAP1 or PAK1 could help treat liver fibrosis. In activated rat primary liver myofibroblasts, the YAP1 inhibitor Visudyne verteporfin or a PAK1 inhibitor tool compound...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Company News

Afraxis, Dainippon Sumitomo deal

Afraxis and Dainippon's Sunovion Pharmaceuticals Inc. subsidiary partnered to use Afraxis' Enhanced Spine Platform (ESP) to accelerate Sunovion's preclinical CNS drug discovery process. ESP uses measurement methods for protrusions on neuronal dendrites called dendritic spines...
07:00 , May 13, 2013 |  BC Week In Review  |  Company News

Afraxis, Servier deal

The partners will use Afraxis' Enhanced Spine Platform (ESP) technology to discover treatments for CNS disorders. Afraxis' EPS technology evaluates the preclinical safety and efficacy of CNS compounds by quantifying and characterizing the morphology and...
07:00 , May 6, 2013 |  BC Week In Review  |  Company News

Afraxis management update

Afraxis Inc., La Jolla, Calif.   Business: Neurology   Transitioned: Christopher Rex to CSO from principle investigator and director of R&D strategy at Afraxis Holdings, which spun off Afraxis Inc.; and Carmine Stengone to president and CEO...
07:00 , Apr 4, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Fragile X syndrome Fragile X mental retardation 1 (FMR1); p21 protein (Cdc42 Rac)-activated...
08:00 , Feb 18, 2013 |  BioCentury  |  Finance

Rule of three

Rule of three Less than two months into 2013, Avalon Ventures has completed a hat trick of exits. The third score was last week's partnership between portfolio company RQx Pharmaceuticals Inc. and the Genentech Inc. unit...
08:00 , Feb 14, 2013 |  BC Innovations  |  Targets & Mechanisms

Statins for fragile X

Researchers at the Massachusetts Institute of Technology have mouse data showing that the cholesterol drug lovastatin can correct fragile X syndrome.1 The findings add to a growing list of unconventional strategies for treating this common...
08:00 , Feb 4, 2013 |  BioCentury  |  Finance

Early bird Avalon

Early bird Avalon Avalon Ventures has hit the ground running in 2013 with two exits thus far and a third waiting in the wings. Just three weeks after BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) bought Zacharon Pharmaceuticals Inc., Genentech...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

Afraxis, Genentech, Roche deal

Roche's Genentech unit acquired from Afraxis its therapeutic business, which comprises a portfolio of compounds against undisclosed, novel targets that Afraxis said covers a range of neurology, inflammation and cancer indications. Afraxis is eligible to...